Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P41440
UPID:
S19A1_HUMAN
Alternative names:
Cyclic dinucleotide:anion antiporter SLC19A1; Folate:anion antiporter SLC19A1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; Solute carrier family 19 member 1
Alternative UPACC:
P41440; B2R7U8; B7Z8C3; E9PFY4; O00553; O60227; Q13026; Q9BTX8
Background:
The Reduced folate transporter, known as SLC19A1, plays a crucial role in cellular uptake of folate and antifolate drugs like methotrexate. It operates as an antiporter, facilitating the import of reduced folates and cyclic dinucleotides by exporting organic anions. This protein is essential for maintaining folate homeostasis and supporting immune responses.
Therapeutic significance:
SLC19A1's dysfunction is linked to megaloblastic anemia, a condition treatable with oral folate. Understanding its mechanism could enhance the efficacy of antifolate therapies in cancer treatment and improve management of folate-related disorders.